About the Program

This case-based program was developed by the Canadian Neurological Science Federation and includes 1 module with 20 questions.

Estimated completion time: 2.0 hours. Complete the program at your pace by saving your progress at any time.

Planning Committee

• Dr. Santanu Chakraborty, Neuroradiologist, Ottawa (ON)
• Dr. Rafael Glikstein, Neuroradiologist, Ottawa (ON)
• Dr. Alex Henri-Bhargava, Neurologist, Victoria (BC)
• Dr. Andrew Kirk, Neurologist, Saskatoon (SK)
• Dr. Sara Mitchell, Neurologist, Toronto (ON)

Learning Objectives

This activity will allow participants to:

1. Use clinical tools to assess signs and symptoms for diagnosis of Alzheimer's disease (AD).
2. Assess the role of different biomarkers in the detection and diagnosis of AD.
3. Interpret neuroimaging findings to detect structural abnormalities associated with AD.
4. Explain the use of nonpharmacological and symptomatic interventions for AD.
5. Discuss the status of emerging disease-modifying therapies (DMTs) and identify potential associated adverse events such as amyloid-related imaging abnormalities – edema/effusion (ARIA-E) and amyloid-related imaging abnormalities – hemorrhagic (ARIA-H).
6. Explain how and when to monitor disease progression and determine the next steps in clinical management.

Key Features

• Case-Based Learning: Increase your knowledge through a case-based scenario, including diagnosis, disease progression, patient monitoring, non-pharmacological interventions, neuroimaging, and treatment options, including novel disease-modifying therapies.
• Test Your Knowledge: Assess your understanding with knowledge and practice-based questions. Receive immediate feedback tailored to your answers, and links to resources and guidelines to further solidify your learnings.
• Flexible and convenient: Pause and resume at your pace, save your progress, and continue at a later time.
• Certification: Complete the program and the evaluation form to receive your certificate of completion and a detailed report of your answers.